Acesso livre
Acesso livre

Covid-19 (Temas de Saúde Pública)

Em vez de quarentena para estudantes expostos à Covid, algumas escolas estão tentando “testar-para-ficar”.

21 Out, 2021 | 11:27h

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay – CNN

Conteúdos relacionados:

Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – “Test-to-stay could dramatically reduce close contact quarantines”.

Opinion | Data from routine Covid testing can help schools stay open this year.

Estudo do CDC | Vacina da Pfizer mostrou 93% de efetividade contra internações por Covid-19 entre crianças de 12 a 18 anos.

20 Out, 2021 | 12:12h

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 – CDC Morbidity and Mortality Weekly Report

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo de coorte | A efetividade da vacinação heteróloga AstraZeneca (AZ)/mRNA foi mais significativa (68%) do que a vacinação homóloga AZ/AZ (50%) contra Covid-19 sintomática na Suécia.

20 Out, 2021 | 12:08h

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study – The Lancet Regional Health Europe

Comentário: High effectiveness of mix-and-match COVID-19 vaccines – UMEA University

Conteúdos relacionados:

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

 

Deve-se misturar e combinar a dose de reforço da vacina?

20 Out, 2021 | 12:06h

Should You Mix and Match Your Booster Shot? – The Atlantic

Conteúdos relacionados:

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

[Preprint] Estudo observacional no Brasil mostrou que a efetividade ajustada da vacina da J&J foi de 50,9% contra Covid-19 sintomática, 72,9% para internações, 92,5% para admissão em UTI, 88,7% para ventilação mecânica e 90,5% para morte.

20 Out, 2021 | 12:05h

Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design – medRxiv

Covid-19: nova mutação da variante Delta sob observação atenta no Reino Unido.

20 Out, 2021 | 12:03h

Covid-19: New mutation of Delta variant under close watch in UK – BBC

Editorial | Preparação para a “doença X”.

19 Out, 2021 | 12:50h

Preparing for “Disease X” – Science

Vacinas da China contra a COVID foram cruciais – agora, a imunidade está diminuindo.

19 Out, 2021 | 12:49h

China’s COVID vaccines have been crucial — now immunity is waning – Nature

Conteúdos relacionados:

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Comissão BJS sobre cirurgia e cuidado perioperatório pós-COVID-19.

19 Out, 2021 | 12:47h

BJS commission on surgery and perioperative care post-COVID-19 – British Journal of Surgery

Conteúdo relacionado: Cohort Study: Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumor types in 61 countries.

 

Comentário no Twitter

 

Vacina da J&J contra COVID-19: FDA recomenda dose de reforço para adultos acima de 18 anos pelo menos 2 meses depois da vacinação com dose única.

18 Out, 2021 | 08:55h

Comunicado de imprensa: Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Comentários:

FDA panel endorses booster shot for J&J COVID-19 vaccine – Associated Press

The Johnson & Johnson one-dose vaccine offers good protection now. A booster shot will maximize that, experts say – CNN

FDA advisers recommend J&J Covid-19 vaccine boosters, talk mix and match boosters – CNN

Conteúdo relacionado: [Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.